Literature DB >> 1122483

Elevated IGA in carcinoma of the nasopharynx.

W M Wara, D W Wara, T L Phillips, A J Ammann.   

Abstract

Fourteen patients with nasopharyngeal carcinoma were evaluated immunologically prior to standard radiotion therapy. All had elevations of serum IgA, ranging from 300 mg/100 ml to 1000 mg/100 ml, with a mean value of 549 mg/100 ml. Seven patients demonstrated depression of cell-mediated immunity as measured by delayed hypersensitivity skin tests, total lymphocyte count, in vitro stimulation with PHA, and T-cell rosette formation. Elevation of serum IgA associated with depression of cell mediated immunity may be characteristic of patients with nasopharyngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122483     DOI: 10.1002/1097-0142(197505)35:5<1313::aid-cncr2820350510>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138.

Authors:  R Dardari; W Hinderer; D Lang; A Benider; B El Gueddari; I Joab; A Benslimane; M Khyatti
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Serum immunoglobulins in brain tumours.

Authors:  S Manjula; A R Aroor; A Raja; S N Rao; A Rao
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

3.  Humoral immune response in Epstein-Barr virus infections. I. Elevated serum concentration of the IgG1 subclass in infectious mononucleosis and nasopharyngeal carcinoma.

Authors:  W P Kaschka; R Hilgers; F Skvaril
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

4.  Epstein-Barr virus antibody patterns preceding the diagnosis of nasopharyngeal carcinoma.

Authors:  C K Chan; N Mueller; A Evans; N L Harris; G W Comstock; E Jellum; K Magnus; N Orentreich; B F Polk; J Vogelman
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

Review 5.  The promise of a prophylactic Epstein-Barr virus vaccine.

Authors:  Henry H Balfour; David O Schmeling; Jennifer M Grimm-Geris
Journal:  Pediatr Res       Date:  2019-10-03       Impact factor: 3.756

6.  Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma.

Authors:  H C Ho; M H Ng; H C Kwan
Journal:  Br J Cancer       Date:  1978-03       Impact factor: 7.640

7.  Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.

Authors:  H C Ho; M H Ng; H C Kwan; J C Chau
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.